Navigation Links
New data suggests interferon-free therapy around the corner for HCV patients
Date:4/19/2012

A, et al 'ALISPORIVIR (ALV) plus PEG-INTERFERON/RIBAVIRIN (PR) in HCV G1 treatment-experienced patients achieves primary endpoint with superior efficacy at treatment week 12 compared to retreatment with PR'.
  • In Pawlotsky J-M, et al, 88% of treatment-nave HCV GT2 or 3 patients achieved SVR 12 after treatment with Alisporivir and RBV. In Alberti A, et al, 70% of null non-responders achieved cEVR when treated with Alisporivir, IFN and RBV.

    AI444040

    • Sulkowski M, et al 'Potent viral suppression with all-oral combination of DACLATASVIR (ns5a inhibitor) and GS-7977 (ns5b inhibitor), +/-RIBAVIRIN, in treatment-nave patients with chronic HCV GT1, 2, or 3'
    • Treatment-nave HCV GT1, 2, and 3 patients given an IFN- and RBV-free once-daily combination of DACLATASVIR and GS-7977 for 24 weeks achieved high rates of early virologic response (HCV RNA detectable at week 4 but undetectable at week 12 EVR) by mITT analysis: 97% EVR in GT1, 90% in GT2 and 3.

    The combination of PegIFN-α and ribavirin (RBV) is the current standard of care for chronic HCV(7), but is associated with a number of side effects including flu-like symptoms, psychiatric manifestations, autoimmune reactions, and hematologic toxicities.(8,9) Between 20-40% of patients require a dose reduction or temporary interruption in their PegIFN-α and ribavirin (RBV) treatment(10) and in 10-14% of patients, side effects are so severe that treatment must be discontinued.(8,9)

    However, studies have shown that achieving a virologic response in chronic HCV is much more dependent on the dose of IFN-α(11)/PegIFN-α(12,13,14) than RBV(15,16,17,11,18). As such, PegIFN-α free therapy is highly anticipated by healthcare professionals and patients alike.

    EASL's Secretary General Professor Mark Thursz commented on the exciting new data being showcased at the congress: "In the future, patients can look forward to all oral treatment regime
    '/>"/>


  • Contact: Travis Taylor
    easlpressoffice@cohnwolfe.com
    44-789-438-6428
    European Association for the Study of the Liver
    Source:Eurekalert

    Page: 1 2 3

    Related biology news :

    1. Approach to diabetes self-management too narrow, study suggests
    2. Study suggests why some animals live longer
    3. New insight into mechanisms behind autoimmune diseases suggests a potential therapy
    4. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
    5. Molecules role in cancer suggests new combination therapy
    6. Geological cycle causes biodiversity booms and busts every 60 million years, research suggests
    7. TGen-led study suggests origins of MRSA strain in food animals
    8. A look back suggests a sobering future of wildfire dangers in US west
    9. New study suggests EU biofuels are as carbon intensive as petrol
    10. Animal study suggests that newborn period may be crucial time to prevent later diabetes
    11. Vitamin D study suggests no mortality benefit for older women
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2014)... Cancer Center researchers may have discovered a new way ... vulnerable by deficient DNA repair. , The findings were ... , The study, led by James E. Hansen, ... of Medicine, found that cancer cells with deficient DNA ... genetic damage) were significantly more vulnerable to attack by ...
    (Date:9/2/2014)... FL, September 2, 2014 In a new study ... from the Florida campus of The Scripps Research Institute ... cells into unique manufacturing sites for molecules that can ... a cell as a reaction vessel and a disease-causing ... a diseased cell," said TSRI Professor Matthew Disney.,"Because the ...
    (Date:9/2/2014)... sequence their genetic information. How is it possible ... parts of the body are so different? While every ... additional regulatory layer exists that determines which of the ... modifications of genome-bound histone proteins or the DNA itself ... top of the genetic information and is thus called ...
    Breaking Biology News(10 mins):Sabotage as therapy: Aiming lupus antibodies at vulnerable cancer cells 2Scripps Florida scientists make diseased cells synthesize their own drug 2Throwing a loop to silence gene expression 2
    ... assessment of malnutrition, created by researchers at Penn State, ... diagnosis and treatment. Up to 50 percent of ... be malnourished, according to Gordon Jensen, professor and head ... confusion exists in the clinical community on how to ...
    ... seeking to refine and improve lung-cancer screening by combining a ... more effectively. The trial combines a CT chest scan and ... to build on recent research demonstrating that CT screening alone ... CT screening of high-risk patients can reduce lung-cancer deaths. But ...
    ... heel within our cells that bacteria are able to exploit ... their findings could lead to the development of new anti-infective ... resistance. University of Manchester researchers studied Listeria ... listeriosis in humans when digested and found they are ...
    Cached Biology News:Researchers unveil new assessment for diagnosing malnutrition 2Trial seeks improved lung-cancer screening by combining imaging and biomarkers 2
    (Date:9/2/2014)... NEW PROVIDENCE, N.J. , Sept. 2, 2014 /PRNewswire/ ... sponsor for MassBio,s 20th Annual Golf Classic, a major ... The event will be held on September 5 at ... Massachusetts . The MassBioEd Foundation ... through educational programs, workforce development, and lifelong ...
    (Date:9/2/2014)... a billionth of a meter in size, are around ... benefit human health, as in some innovative early cancer ... viruses, air pollution, traffic emissions, cosmetics, sunscreen and electronics. ... St. Louis, led by Lan Yang, PhD, the Das ... Engineering, and their collaborators at Tsinghua University in China ...
    (Date:9/2/2014)... including University of Oregon chemist Geraldine Richmond, have ... self-assembling, synthetic proteins called peptoid nanosheets that mimic ... -- detailed this week in a paper placed ... of the National Academy of Sciences -- ... the two-dimensional peptoid nanosheets that can be used ...
    (Date:9/2/2014)... NEW YORK , September 2, 2014 ... Market Study on Membrane Technology in Pharmaceutical, Biopharma and ... Witness Highest Growth by 2019" the global membrane technology market for ... 7,029.9 million in 2014 and is expected to grow ... to reach an estimated value of USD 10,886.0 million ...
    Breaking Biology Technology:Linde helps fund STEM education in Massachusetts 2Linde helps fund STEM education in Massachusetts 3Engineers develop new sensor to detect tiny individual nanoparticles 2Engineers develop new sensor to detect tiny individual nanoparticles 3UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5
    ... ... ... var shortURL ... we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for ...
    ... ... ... var shortURL = ""; BitlyCB.alertResponse ... grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var key in ...
    ... in a row, a pair of Rensselaer students took ... held by the American Society of Mechanical Engineers (ASME). ... Jaron Kuppers won top honors in the national competition ... process. The SET process offers a new method for ...
    Cached Biology Technology:YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 2YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 3YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 4YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 5YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 6YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 7YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 8YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 9Medivir: R&D Day 2Medivir: R&D Day 3Medivir: R&D Day 4Medivir: R&D Day 5Medivir: R&D Day 6Medivir: R&D Day 7Medivir: R&D Day 8Rensselaer mechanical engineers win first place at ASME student manufacturing design competition 2Rensselaer mechanical engineers win first place at ASME student manufacturing design competition 3Rensselaer mechanical engineers win first place at ASME student manufacturing design competition 4
    Kit for testing the ability of a compound to simulate lipolysis in cultured human adipocytes. Kit contains controls, buffers and reagents for detecting glycerol and non-esterified free fatty acids. A...
    ... The Experion Pro260 analysis kit for 10 ... to perform protein analysis with the Experion ... Pro260 microfluidic chips, 3 x 520 microliters ... microliters Pro260 ladder (10-260 kD), 400 microliters ...
    Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
    ... Staccato Mini-Workstations provide fast and reliable ... proteomics and drug development laboratories. Staccato ... instrumentation to automate basic liquid handling ... are controlled with either Caliper's time ...
    Biology Products: